ACM
AMLX icon

ACT Capital Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

ACT Capital Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-9,000
Closed -$125K – 63
2026
Q1 		$125K Hold
9,000
– – 0.1% 50
2025
Q4 		$109K Buy
+9,000
New +$122K 0.09% 49

Other funds holding AMLX

IGAM
iA Global Asset Management Quebec, Quebec, Canada $8.42B AUM 47.61% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
PPWP
Premier Path Wealth Partners Madison, New Jersey $870M AUM 30% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM

ACT Capital Management's AMLX Position: Q2 2026 in Review

ACT Capital Management sold out of Amylyx Pharmaceuticals (AMLX) in Q2 2026, closing a stake of 9,000 shares — an estimated $125K sold.

ACT Capital Management first reported a position in AMLX in Q4 2025 and held it in 2 quarters. The position peaked at $125K in Q1 2026. 26 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • ACT Capital Management reported no remaining Amylyx Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • ACT Capital Management sold 9,000 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $125K.
  • ACT Capital Management first reported a position in Amylyx Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • ACT Capital Management's Amylyx Pharmaceuticals position peaked at $125K in Q1 2026.
  • 26 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on ACT Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.